Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyVisceral SurgeryDiseasePeritoneal MesotheliomaSubgroupICD10C45.1MeSHMesothelioma, MalignantSequenceChemotherapyChemo-substanceAtezolizumabBevacizumabCisplatinDoxorubicinChemo-substanceAtezolizumabBevacizumabCisplatinDoxorubicinChemo-substanceAtezolizumabBevacizumabCisplatinDoxorubicinChemo-substanceAtezolizumabBevacizumabCisplatinDoxorubicinNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateNo. Substances15Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseintraoperativTherapy intentionpalliativeRisksAnemia Hb below 8g/dlArthalgiaAstheniaConstipationDiarrheaEmetogenicity (MASCC/ESMO)HepatotoxicityHypertensionIncrease AminotransferasesLeukopeniaLymphopeniaNephrotoxicityPainPancreatitisProteinuriaPruritusThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorChicago Consensus Working GroupFeldman AGilani SRaghav KDiseasePeritonealmesotheliomPeritonealmesotheliom, ECOG 0-2Peritonealmesotheliom, Karnofsky > 50Peritonealmesotheliom, Zweitlinie oder höher, ECOG 0-1OriginChicago Consensus Working GroupPeritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, UKSurgical Metabolism Section, National Cancer Institute, National Institutes of Health, Bethesda, MDThe University of Texas MD Anderson Cancer Center, Houston, TexasProtocols in Revision 4 protocols foundProtocols under revision.Atezolizumab 1200 / Bevacizumab 15, peritoneal mesothelioma (PID1934 V1.0)HIPEC - Cisplatin 100, peritoneal mesothelioma (PID2776 V1.1)HIPEC - Cisplatin 250, Peritoneal Mesothelioma (PID2795 V1.1)HIPEC - Cisplatin 50 / Doxorubicin 15, peritoneal mesothelioma (PID2708 V1.0)
